Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD

Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD

Introduction: The effects of long-term and uninterrupted tolvaptan treatment on autosomal dominant polycystic kidney disease (ADPKD) are unclear. Therefore, a more than 3-year continuous treatment study was performed. Methods: From the Kyorin University cohort, 299 patients were surveyed and 179 pat...

Full description

Bibliographic Details
Main Authors: Eiji Higashihara, Kikuo Nutahara, Masayuki Itoh, Takatsugu Okegawa, Mistuhiro Tambo, Tsuyoshi Yamaguchi, Yu Nakamura, Satoru Taguchi, Shinya Kaname, Kenichi Yokoyama, Tatsuya Yoshioka, Hiroshi Fukuhara
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:Kidney International Reports
Subjects:
autosomal dominant polycystic kidney disease (ADPKD)
estimated glomerular filtration rate (eGFR)
sex
tolvaptan
total kidney volume (TKV)
vasopressin
Online Access:http://www.sciencedirect.com/science/article/pii/S246802492101559X

Internet

http://www.sciencedirect.com/science/article/pii/S246802492101559X

Similar Items